A Prospective, Multi-center, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis

The goal of this clinical trial is to learn whether a study drug called Compound Betamethasone (also known as Diprospan) works to treat pulmonary sarcoidosis in people with early-stage disease (stage I or II). It will also learn about its safety compared to the standard treatment, prednisone.

The main questions it aims to answer are:

• How much does the study drug improve lung function (measured by a test called FVC%) after 24 weeks of treatment?
• How does it compare to prednisone in controlling symptoms, reducing chest lymph node swelling, and preventing relapse? Researchers will compare Compound Betamethasone injections (given once every 4 weeks) to prednisone pills (taken daily with a gradual dose reduction).

Participants will:

• Receive either the study drug injection or prednisone pills for 24 weeks
• Visit the clinic for checkups and lung function tests at weeks 6, 12, and 24
• Have chest CT scans and blood tests to monitor their condition and any side effects
• Be followed up for additional 24 weeks (up to week 48) to see if the disease comes back after treatment stops